Sanofi Wins US Approval for Novel Therapy Designed to Delay Type 1 Diabetes Progression
The French pharmaceutical group said US regulators granted accelerated approval for Tzield, the first approved treatment intended to delay the onset of stage three type one diabetes in recently diagnosed children.